These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21883747)

  • 1. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient.
    Maguire M; Franz T; Hains DS
    Pediatr Transplant; 2012 Sep; 16(6):E217-20. PubMed ID: 21883747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
    Ciftci HS; Karadeniz MS; Tefik T; Caliskan Y; Yazıcı H; Demir E; Turkmen A; Nane I; Oguz FS; Aydin F
    Transplant Proc; 2017 Apr; 49(3):490-496. PubMed ID: 28340819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
    Takahashi K; Yano I; Fukuhara Y; Katsura T; Takahashi T; Ito N; Yamamoto S; Ogawa O; Inui K
    Drug Metab Pharmacokinet; 2007 Dec; 22(6):441-4. PubMed ID: 18159131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
    Bosó V; Herrero MJ; Bea S; Galiana M; Marrero P; Marqués MR; Hernández J; Sánchez-Plumed J; Poveda JL; Aliño SF
    Drug Metab Dispos; 2013 Feb; 41(2):480-7. PubMed ID: 23175667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
    Itagaki F; Homma M; Yuzawa K; Fukao K; Kohda Y
    Transplant Proc; 2002 Nov; 34(7):2777-8. PubMed ID: 12431607
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
    Hosohata K; Masuda S; Katsura T; Takada Y; Kaido T; Ogura Y; Oike F; Egawa H; Uemoto S; Inui K
    Drug Metab Dispos; 2009 Apr; 37(4):821-6. PubMed ID: 19139162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
    Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
    J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
    Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
    Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
    Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
    Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
    Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
    Hosohata K; Masuda S; Yonezawa A; Sugimoto M; Takada Y; Kaido T; Ogura Y; Oike F; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2009; 24(5):458-63. PubMed ID: 19881258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of the proton pump inhibitors: a systematic review.
    Chong E; Ensom MH
    Pharmacotherapy; 2003 Apr; 23(4):460-71. PubMed ID: 12680476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M
    Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
    Hosohata K; Masuda S; Ogura Y; Oike F; Takada Y; Katsura T; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2008; 23(2):134-8. PubMed ID: 18445994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.